A recent phase I clinical trial evaluated the combination of the autophagy inhibitor hydroxychloroquine and a histone deacetylase (HDAC) inhibitor (entinostat) with regorafenib in metastatic CRC patients. Here, HDAC9 is linked to colorectal carcinoma.